Why the study?
Does TLE3 expression predict taxane responsiveness or survival in patients with angiosarcoma?
Does TLE3 expression predict taxane responsiveness or survival in patients with angiosarcoma?
TLE3 expression varies significantly by angiosarcoma subtype but does not predict taxane response, whereas the vasoformative subtype is associated with improved 5-year survival.
No takes yet. Share an insight, caveat, or question.
TLE3 expression should not guide taxane use in angiosarcoma; extends subtype differences but leaves predictive utility open.
Shon et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: